| Literature DB >> 34888394 |
Parham Sendi1, Rossella Baldan1, Marc Thierstein2, Nadja Widmer3, Peter Gowland3, Brigitta Gahl4, Annina Elisabeth Büchi5, Dominik Güntensperger4, Manon Wider1, Manuel Raphael Blum6,7, Caroline Tinguely3, Cédric Maillat8, Elitza S Theel9, Elie Berbari10, Ronald Dijkman1, Christoph Niederhauser1,3.
Abstract
BACKGROUND: Protests and police fieldwork provide a high-exposure environment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. In this cross-sectional analysis, we investigated the seroprevalence among a police cohort, and sociodemographic, work, and health-related factors associated with seropositivity.Entities:
Keywords: anti-SARS-CoV-2 antibodies; coronavirus disease 2019; police officers; seroprevalence
Year: 2021 PMID: 34888394 PMCID: PMC8651158 DOI: 10.1093/ofid/ofab524
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Demographic Characteristics and Anti-Nucleocapsid Protein Immunoglobulin G Status for 978 Employees of the Bern Cantonal Police,
| Characteristic | No. of Responses | Study Participants (N=978) | Seropositive (n=126) | Seronegative (n=852) |
|
|---|---|---|---|---|---|
| Age, y, mean (SD) | 880 | 40 (8.9) | 39 (9.0) | 41 (8.8) | .12 |
| Sex | 973 | .67 | |||
| Female | 270 (28) | 37 (29) | 233 (27) | ||
| Male | 703 (72) | 89 (71) | 614 (72) | ||
| Comorbidity | |||||
| BMI, kg/m2, mean (SD) | 975 | 26 (3.5) | 26 (3.3) | 26 (3.5) | .46 |
| Diabetes mellitus | 972 | 13 (1.3) | 3 (2.4) | 10 (1.2) | .23 |
| Arterial hypertension | 973 | 78 (8.0) | 10 (7.9) | 68 (8.0) | 1.00 |
| Cardiovascular disease | 971 | 17 (1.7) | 3 (2.4) | 14 (1.6) | .47 |
| Lung disease | 973 | 27 (2.8) | 2 (1.6) | 25 (2.9) | .56 |
| Immunosuppression | 971 | 12 (1.2) | 2 (1.6) | 10 (1.2) | .66 |
| Other disease | 973 | 101 (10) | 10 (7.9) | 91 (11) | .43 |
| No comorbidity | 978 | 761 (78) | 100 (79) | 661 (78) | .73 |
| Education | 974 | .16 | |||
| Police academy | 795 (81) | 114 (90) | 681 (80) | ||
| Security assistant school | 53 (5.4) | 4 (3.2) | 49 (5.8) | ||
| University degree | 63 (6.4) | 3 (2.4) | 60 (7.0) | ||
| Merchant | 32 (3.3) | 2 (1.6) | 30 (3.5) | ||
| Craftsman | 18 (1.8) | 2 (1.6) | 16 (1.9) | ||
| Other | 13 (1.3) | 1 (0.79) | 12 (1.4) | ||
| No. of years working for the police, median (IQR) | 915 | 11 (7.0–19) | 11 (7.0–20) | 11 (6.5–19) | .75 |
| Working region within the canton | 963 |
| |||
| Seeland, Bernese Jura | 170 (17) | 37 (29) | 133 (16) | ||
| Mittelland, Emmental, Oberaargau | 193 (20) | 22 (17) | 171 (20) | ||
| Bernese Oberland | 132 (13) | 14 (11) | 118 (14) | ||
| Region Bern | 229 (23) | 31 (25) | 198 (23) | ||
| Bern City | 239 (24) | 22 (17) | 217 (25) | ||
| Department | 973 |
| |||
| Regional police | 649 (66) | 90 (71) | 559 (66) | ||
| Criminal police | 118 (12) | 20 (16) | 98 (12) | ||
| Traffic, environment, prevention | 72 (7.4) | 10 (7.9) | 62 (7.3) | ||
| Interdepartmental | 120 (12) | 6 (4.8) | 114 (13) | ||
| Other | 14 (1.4) | 0 (0.00) | 14 (1.6) | ||
| Main activity | 939 |
| |||
| Fieldwork | 559 (57) | 84 (67) | 475 (56) | ||
| Office work | 380 (39) | 39 (31) | 341 (40) | ||
| % of working hours in the field, median (IQR) | 952 | 50 (20–70) | 60 (30–70) | 50 (20–70) |
|
| % of working hours in the office, median (IQR) | 976 | 50 (30–80) | 40 (30–70) | 50 (30–80) |
|
Data are presented as No. (%) unless otherwise indicated. Values in bold are statistically significant (P < .05).
Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation.
All except 2 individuals with anti-nucleocapsid protein (NCP) antibodies also displayed anti-spike antibodies (Supplementary Figure A).
Two vaccinated individuals (both anti-NCP antibody negative) were included in this analysis.
Figure 1.Map of the canton of Bern in Switzerland. The different colors indicate the corresponding geographic regions. The overall seroprevalence was 12.9% (ie, 126 of 978 samples displayed anti-nucleocapsid protein antibodies). Responses of 963 study participants were available; 15 seronegative individuals did not provide their geographic working district.
Clinical Symptoms Reported by Study Participants During the Coronavirus Disease 2019 Pandemic
| Symptoms | No. of Responses | Study Participants (N=978) | Seropositive (n=126) | Seronegative (n=852) |
|
|---|---|---|---|---|---|
| Fever | 954 | 130 (13) | 41 (33) | 89 (11) |
|
| Chills | 949 | 137 (14) | 41 (33) | 96 (11) |
|
| Fatigue | 959 | 547 (56) | 102 (81) | 445 (53) |
|
| Muscle or body aches | 947 | 142 (15) | 47 (37) | 95 (11) |
|
| Sore throat | 963 | 406 (42) | 56 (44) | 350 (41) | .56 |
| Congestion or runny nose | 959 | 479 (49) | 73 (58) | 406 (48) |
|
| New loss of taste or smell | 948 | 107 (11) | 80 (63) | 27 (3.2) |
|
| Shortness of breath or difficulty breathing | 948 | 135 (14) | 42 (33) | 93 (11) |
|
| Chest pain | 947 | 129 (13) | 33 (26) | 96 (11) |
|
| Cough or other respiratory symptoms | 937 | 84 (8.6) | 20 (16) | 64 (7.6) |
|
| Headache | 955 | 263 (27) | 75 (60) | 188 (22) |
|
| Nausea or vomiting | 945 | 65 (6.7) | 13 (10) | 52 (6.1) | .09 |
| Abdominal pain | 941 | 71 (7.3) | 8 (6.3) | 63 (7.4) | .85 |
| Diarrhea | 945 | 133 (14) | 26 (21) | 107 (13) |
|
Data are presented as No. (%) unless otherwise indicated. Values in bold are statistically significant (P < .05).
Two vaccinated individuals (both anti-nucleocapsid protein antibody negative) were included in this analysis.
Comparison of Seropositive (ie, Seroconversion) and Seronegative (ie, No Seroconversion) Individuals After Contact With a Proven or Presumed Coronavirus Disease 2019 Case
| Reasons for Being in Quarantine | No. of Responses | Study Participants (N=978) | Seropositive (n=126) | Seronegative (n=852) |
|
|---|---|---|---|---|---|
| Contact with a person living in the same household who had COVID-19 (proven with a test) | 978 | 102 (10) | 57 (45) | 45 (5.3) |
|
| Contact with a person living in the same household who had presumable COVID-19 (not proven with a test) | 977 | 105 (11) | 20 (16) | 85 (10) | .06 |
| Contact with a person at work who had COVID-19 (proven with a test) | 977 | 364 (37) | 43 (34) | 321 (38) | .49 |
| Contact with a person at work who had presumable COVID-19 (not proven with a test) | 976 | 192 (20) | 22 (17) | 170 (20) | .55 |
Data are presented as No. (%) unless otherwise indicated. Values in bold are statistically significant (P < .05).
Abbreviation: COVID-19, coronavirus disease 2019.
Two vaccinated individuals (both anti-nucleocapsid protein antibody negative) were included in this analysis.
Figure 2.Results of neutralization assays performed with serum of study participants (n=126) and isogenic severe acute respiratory syndrome coronavirus 2 viruses harboring either the D614G spike, the full-length B.1.1.7 spike (Alpha variant), or the full-length B.1.351 spike (Beta variant). Each dot represents the results of a study participant. Each sample was tested against all 3 strains. The red dashed line reflects the limit of detection. The numbers on the y-axis indicate the highest dilution of serum demonstrating neutralization activity. The box plots display the distribution of data between the first quartile, median, and third quartile. A Wilcoxon rank-sum and signed-rank test was performed to compare the groups. ∗∗∗∗P<.0001. Abbreviation: wt-S, wild-type spike.
Figure 3.Results of neutralization assays categorized according to selected cutoff electrochemiluminescence immunoassay test values of anti-nucleocapsid protein (NCP) antibodies (cutoff index ≤37.5 and >37.5) and anti-spike (S) antibodies (≤65 U/mL and >65 U/mL). The combination of these values result in 4 groups. The box plots display the distribution of data between the first quartile, median, and third quartile of serum neutralization titers of each group. The numbers on the y-axis indicate the highest serum dilution demonstrating neutralization activity.